Samuel H. Zwillich - Concepedia

Author

Samuel H. Zwillich

Also Known As

S H Zwillich, S Zwillich, S. H ZWILLICH, S. H. Zwillich, S. Zwillich, S.H. Zwillich, SAMUEL H. ZWILLICH, Samuel H Zwillich, Samuel H. Zwillich, Samuel Zwillich

111

Publications

9.8K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Metroplex Clinical Research Center Albany Medical Center Hospital Seoul National University Stanford University

About

Samuel H. Zwillich is an author at Pfizer (United States) specializing in medicine, immunology, and rheumatology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.9K
2	Immunology	7	7	1.6K
3	Pathology	3	3	66
4	Cell Biology	2	2	386
5	Microbiology	2	2	25

Samuel H. Zwillich

Publications

8.8K

Citations

H-Index

Page 1

	Year	Citations
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis Roy Fleischmann, Joel M. Kremer, John J. Cush, New England Journal of Medicine	2012	1K
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, New England Journal of Medicine	2012	922
Tofacitinib versus Methotrexate in Rheumatoid Arthritis Eun Bong Lee, Roy Fleischmann, Stephen Hall, New England Journal of Medicine	2014	761
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman, The Lancet InflammationRheumatologyRheumatoid DisorderAnti-inflammatoryMedicine	2013	714
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, Arthritis & Rheumatism	2013	572
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo Joel M. Kremer, Bradley J. Bloom, Ferdinand C. Breedveld, Arthritis & Rheumatism	2009	541
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis Joel M. Kremer, Zhanguo Li, Stephen Hall, Annals of Internal Medicine ImmunologyPharmacotherapyInflammatory ArthritisInflammationRheumatoid Disorder	2013	441
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs Roy Fleischmann, Maurizio Cutolo, Mark C. Genovese, Arthritis & Rheumatism	2011	376
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Jennifer Hodge, Thomas T. Kawabata, Sriram Krishnaswami, PubMed ImmunologyBiological TherapyInflammationRheumatoid DisorderReceptor Tyrosine Kinase	2016	371
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Joel M. Kremer, Stanley Cohen, Bethanie Wilkinson, Arthritis & Rheumatism	2011	343

Page 1